Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Feminizing ovarian tumors and polycystic ovarian disease may cause
endometrial cancer
by abnormal, unopposed endogenous estrogenic stimulation. We reviewed the clinical course of 72
endometrial cancer
patients with a concomitant feminizing ovarian tumor or polycystic ovarian disease and compared tumor characteristics and treatment results with those exhibited by 523 patients treated for
endometrial cancer
alone. With functioning ovarian tumor and with
polycystic ovaries
, the cancer tended to be more often low-grade, low-stage, and superficial than did
endometrial cancer
alone. The high 5-year and 10-year survival rates observed in our functioning ovarian tumor-
polycystic ovary
patients support the conclusion that
endometrial carcinoma
with a coexistent endogenous estrogenic stimulus has a more favorable prognosis (P less than 0.01) than
endometrial carcinoma
alone.
...
PMID:Endometrial cancer associated with feminizing ovarian tumor and polycystic ovarian disease. 19 78
Perimenopausal and postmenopausal substitutive estrogen treatment is valuable if prescribed according to proper indications and in the proper manner. Studies have shown a correlation between menopausal estrogen treatment and
endometrial cancer
. Siiteri hypothesized that estrone was the estrogen with a specific carcinogenic effect. A study undertaken in California indicates, however, that conjugated estrogens are associated with a lower risk of
endometrial cancer
. There is also strong indications that certain factors predispose a woman to
endometrial cancer
during menopausal estrogen treatment: obesity, the
Stein-Leventhal
syndrone, the Turner syndrome, hirsuitism caused by increased androgen activity, and family history of
endometrial cancer
. Menopausal estrogen treatment is prescribed in cases of menstrual disturbances, neurovegetative or vaso-motor disturbances, psychological disturbances, atrophy of the urogenital tract, or cases of calcium or fat metabolism disturbances which could lead to osteoporosis or arteriosclerosis.
...
PMID:[Estrogen substitution and endometrial carcinoma]. 21 33
1. It has become evident that the estrogen secreting tumors of the ovary are associated with
endometrial carcinoma
, but this association is most easily observed in the postmenopausal patient where the incidence of carcinoma has been reported at 10.3% (1. 02) to 24% (83). 2. The most consistent association of
endometrial carcinoma
is with polycystic ovarian disease, where 19 (34), 21 (152), and 25% (150) of young women with
endometrial carcinoma
had
Stein-Leventhal syndrome
(67). 3. A very significant discovery became known in 1967 when the peripheral aromatization of delta4 androstenedione to estrone was reported by Kase (94) and MacDonald (111,112). Since that time we have learned that
endometrial carcinoma
patients have an increased peripheral conversion (139) (0.1% compared to 0.027%), which is similar to that found in obese and aging patients, by Hemsell, et al (77). This can be 2 to 4 times greater than the young adult or the patient without cancer. Estrone produced peripherally in normal postmenopausal women can amount to 40-60 microng/day and rise as high as 120-180 microng/day in the endometrial neoplasia group (39). Similarly patients with
polycystic ovary disease
, hyperthecosis and lipoid cell tumors of the ovary demonstrate androgen excess with extraglandular conversion to estrone (2). 4. It has become apparent that the principal estrogen in the postmenopausal patient is estrone and that the estrone-estradiol ratio in the serum is higher in postmenopausal women with corpus cancer than similar patients without cancer (135). Clearly, we must find the effect of this estrone excess at the nuclear "acceptor" level; and does this imbalance create a hormonal environment conducive to the development of
endometrial carcinoma
when age (an extremely important factor) and an oncogenic agent are added? 5. With the lack of ovarian estrogen there is a relative excess of adrenal testosterone, dihydrotestosterone and delta4 androstenedione, the available precursors of extraglandular estrone (1). 6. With the passage of time it appears that
endometrial carcinoma
is associated with hypothalamic "hyperactivity" (31) which exhibits immunologic-biologic dissociation of LH as previously observed in persistent trophoblastic disease when measuring hCG. The significance of this is still unknown. In a like fashion a significant number of the at risk
polycystic ovary disease
patients have an increased LH secretion. 7. Patient susceptibility is required as seen in animal experiments where prolonged administration of stilbestrol is used and still only rabbits and mice developed a malignant change. 8. Long term exogenous estrogen appears to have caused malignant changes in the endometrium, but it was universally given over a prolonged period (4 or more years). The recent retrospective studies demonstrate an association of oral estrogen therapy with
endometrial cancer
, but prospective studies investigating dose and duration of all estrogen preparations need to be undertaken. 9...
...
PMID:Estrogen and endometrial carcinoma. 32 64
Six cases of adenocarcinoma of the endometrium associated with the
Stein-Leventhal syndrome
are presented. The average age of the patients was 27.8 years. All patients were treated surgically; 2 had preoperative intracavitary irradiation, and 1 had postoperative intravaginal cesium-137 application. At follow-up, ranging from 1 to 15 years, all patients are alive and free of disease. Almost 90% of endometrial adenocarcinoma in association with the
Stein-Leventhal syndrome
is well differentiated, and appropriate treatment is associated with a good prognosis. Conservative therapy carries the risk of progression of the cancer to more advanced stages and has very little to offer for future fertility. It is suggested that these patients be treated as are any other patients with
endometrial cancer
.
...
PMID:Endometrial adenocarcinoma and the Stein-Leventhal syndrome. 61 43
Data on 167 cases of atypical hyperplasia of the endometrium and 292 cases of adenocarcinoma of the endometrium from 1966 to 1977 are presented. In 41 cases of atypical hyperplasia (24.5%) also adenocarcinoma of the endometrium coexisted. The age distribution revealed that atypical hyperplasia was much frequent in the age group from 40--59, and adenocarcinoma of the endometrium from 59--69. Out of 61 cases of theca- and granulosa-cell tumors of the ovary, 13 cases (21.3%) related to atypical hyperplasia or adenocarcinoma of the endometrium. Out of 27 cases of the
Stein-Leventhal syndrome
, 3 cases were atypical hyperplasia, one case adenocarcinoma of the endometrium. The data presented suggest that atypical hyperplasia might be a stage in the development of
endometrial carcinoma
.
...
PMID:[Atypical hyperplasia and endometrial carcinoma (author's transl)]. 75 26
A case-control study of 268 patients with
endometrial cancer
and 268 population controls was conducted during 1988-1990 in Shanghai, China, to evaluate etiologic factors in a population whose risk had not been substantially altered by the use of exogenous estrogens. In spite of this, the major risk factors resembled those found in other studies. The risk of
endometrial cancer
was significantly elevated among nulligravidas (OR = 5.4, 95% CI = 2.0-14.6) and decreased with number of pregnancies (p less than 0.01). Late age at menopause was associated with increased risk, while early age at menarche was unrelated. Use of oral contraceptives for more than 2 years was associated with a reduction in
endometrial cancer
risk (OR = 0.4, 95% CI = 0.1-1.2), while short-term use of oral contraceptives and other methods of contraception were unrelated. Obesity was a strong predictor of risk, with women in the highest quartile of weight having 2.5 times the risk of those in the lowest quartile. In contrast to many other studies, cigarette smokers were at elevated risk (OR = 1.7, 95% CI = 0.9-3.0). Risk was also elevated among women reporting a history of gall-bladder disease,
polycystic ovaries
, menstrual symptoms, and non-estrogen hormone use.
...
PMID:A population-based case-control study of endometrial cancer in Shanghai, China. 187 68
Soskin, in his 1946 textbook, stated that insulin may be regarded as the dominant instrument in the symphony of endocrine action that results in normal carbohydrate metabolism. After almost half a century, great progress in the medical field has revealed that insulin plays more than even he described. Some aspects of important actions of insulin in our field as investigated in our laboratory are summarized below. 1. Role of insulin in reproductive endocrinology. (1) Correlation of insulin and testosterone in normal young women and patients with
polycystic ovary syndrome
(
PCO
). The sum of serum insulin values during 75g OGTT and serum testosterone values were positively correlated in normal women and patients with
PCO
. Glucose transport activities in isolated adipocytes from a typical
PCO
patient were decreased, but insulin binding activities were not, which indicates that insulin resistance in this patients is due to some post-receptor defects. (2) Insulin may be a risk factor of
endometrial carcinoma
. It is well-recognized that several diseases associate with hyperinsulinemia, such as obesity,
PCO
, diabetes mellitus, and hypertension are risk factors for
endometrial carcinoma
. The sum of the insulin values during OGTT was significantly higher in patients with
endometrial carcinoma
than in those without. 2. Role of insulin in perinatal medicine. (1) Increase in insulin secretion during pregnancy. High serum insulin concentration during OGTT, increased secretion of urinary C-peptide, and enhanced staining of insulin in B cells by the PAP method suggest that insulin secretion is enhanced during pregnancy. (2) Insulin resistance during pregnancy. Glucose utilization rate in both pregnant and progesterone-treated rats, as assessed by a glucose clamp technique, is significantly decreased as compared to nonpregnant rats. The technique of 2-deoxyglucose injection revealed that whole body insulin resistance is due to insulin resistance in individual insulin-sensitive tissues. The activities of 3-0-methyl-D-glucose transport in isolated rat skeletal muscle and human adipocytes were found to decrease during late pregnancy, but insulin binding activities were not. These results suggest that insulin resistance during pregnancy is due to some post-receptor mechanisms. (3) Physiological meaning of insulin in fetal growth.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[The role of insulin in reproductive endocrinology and perinatal medicine]. 223 Apr 12
Polycystic ovary syndrome
is a disorder of unknown cause characterized by anovulation, hyperandrogenism, and gonadotropin secretory abnormalities producing oligo-ovulation or anovulation. Hyperinsulinemia and insulin resistance are important features of this syndrome. Because other causes of androgen excess may produce similar clinical and biochemical findings,
PCO
remains a diagnosis of exclusion. Treatment is directed toward relieving symptoms of hyperandrogenemia in order to stimulate ovulation, correcting obesity, and inducing regular menses to reduce the risk of
endometrial cancer
.
...
PMID:Polycystic ovary syndrome. 226 12
This review of
endometrial cancer
summarizes the demographic characteristics of patients with the disease, their hormonal risk factors related to endogenous and exogenous estrogens and medical history, and other risk factors.
Endometrial cancer
increased in incidence in the US in the early 1970s, but then declined again in the last 2 decades. Possible reasons are classification including estrogen- induced hyperplasia, but also increased use of exogenous estrogens primarily in post-menopausal women, who are the predominant victims. Postmenopausal estrogen usage decreased at the same time. The highest incidence occurs in Polynesian women, although US Caucasians have more
endometrial cancer
then Blacks or European women.
Endometrial cancer
is common in women with estrogen-secreting ovarian cancer. Women with
polycystic ovaries
, where the steroid androstenedione is secreted and converted to estrone in peripheral tissues, but progesterone is lacking, are higher risk for endometrial hyperplasia and cancer. Obese women are also at risk (estimated 20-fold), as they have low sex binding globulin and higher estrogen levels. Any exogenous estrogen, by any route, even if stopped for a week per month confers higher risk for
endometrial cancer
, as shown by virtually all case control studies. Very little data exists on the actual effect of taking progestins with postmenopausal estrogens. These tumors are less invasive, more differentiated, and often detected earlier than non-estrogen dependent endometrial cancers. Other putative risk factors, e.g., diabetes, hypertension, gall bladder disease, radiation exposure, and family history of breast cancer have no solid evidence for association. Smoking, however, is associated with a lower risk of
endometrial cancer
.
...
PMID:Epidemiology of endometrial cancer. 257 97
It is important to diagnose hyperandrogenism in women. By disturbing ovulation, it is actually one of the most frequent causes of infertility. In this particular case, its diagnosis has specific implications: sometimes specific treatment is indicated, or the risk of fetal virilization should be prevented. There is always the possibility of a diagnosis of
polycystic ovary
, prompting precautionary measures to be taken that are likely to limit the risks linked to the multifollicular development that is so frequent with this disorder. In addition, hyperandrogenism exposes the patient to various gynecological and general complications:
cancer of the endometrium
, progressive increase in menstrual disturbances and infertility, obesity, metabolic disturbances and probably increase in cardiovascular risks. Certain types of hyperandrogenism give rise to diseases that expose the patient to specific risks: virilizing tumors, Cushing's syndrome, neonatal risks linked to congenital hyperplasia of the adrenal glands. Hyperandrogenism should be borne in mind not only when the clinical picture is that of virilization, but also when there is any disturbance in eugonadal ovulation, whether or not this is manifested as menstrual disturbances or as infertility, and especially whether or not it is accompanied by hirsutism.
...
PMID:[When and why should hyperandrogenism be searched for in women?]. 267 67
1
2
3
4
5
6
7
8
9
10
Next >>